ReviewDiscover oncology2026
Ursolic acid as a multifunctional anticancer agent with insights into molecular mechanisms therapeutic potential and formulation strategies.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this review article is to comprehensively summarize the anticancer potential of Ursolic Acid (UA) by elucidating its underlying molecular mechanisms, therapeutic efficacy, and formulation advancements. It aims to highlight UA’s multifunctional role in modulating key cancer-related pathways and discuss recent progress in nano-formulation strategies designed to overcome its poor solubility and bioavailability, thereby facilitating its clinical translation. This review employs a comprehensive analysis of existing preclinical and limited clinical studies on UA, focusing on its molecular mechanisms and anticancer activities. It systematically examines literature related to key signalling pathways, therapeutic effects, and formulation advancements. Additionally, it evaluates nano-formulation approaches and combination therapies aimed at improving UA’s bioavailability and clinical applicability. The review reveals that UA demonstrates strong anticancer potential by inducing apoptosis, autophagy, and cell cycle arrest through modulation of key pathways like PI3K/Akt/mTOR, STAT3, and NF-κB. It suppresses metastasis, angiogenesis, and epithelial-mesenchymal transition, enhances antioxidant defence, and triggers ROS-mediated apoptosis. UA’s epigenetic modulation contributes to its anti-proliferative effects, while nano formulations improve its solubility, bioavailability, and targeted delivery, with early clinical studies showing good tolerance and preliminary signs of therapeutic benefit.UA emerges as a promising natural anticancer agent capable of targeting multiple molecular pathways involved in tumor growth and progression. Despite its broad preclinical efficacy, its poor solubility and low bioavailability limit clinical application. Advances in nano-formulation strategies have shown potential to overcome these challenges. However, extensive clinical investigations and standardized formulations are essential for successful therapeutic translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.